Feasibility of Pulmonary Interstitial Lymphography-guided Targeting in Stereotactic Ablative Radiation Therapy of Lung Tumors

Abstract

71 patients whose MPLCs were both stage I, overall survival rates were 68.7% at 3 years and 28.1% at 5 years, with median survival time 59.8 months. Survival seemed better for MMPLC than for SMPLC, but this was not statistically different. In multivariate analysis, poor survival was associated with having CFRT for an index tumor (p Z 0.035) and being oxygen-dependent before treatment (p Z 0.019). Survival rates were not different for patients whose index tumors were treated with SABR versus surgery. The most common toxicity of SABR was chest wall pain (21.8% grade 2 and 3% grade 3), followed by pneumonitis (13.5% grade 2 and 3.1% grade 3/4) and dermatitis (9.4% grade 2 and 1% grade 3). Conclusions: SABR produced excellent local control and survival with tolerable toxicity in MPLC and may be potentially curative in some cases. Author Disclosure: Y. Liu: None. P. Balter: None. R. Komaki: None. Q. Xu: None. S. Swisher: None. J. Chang: None.